Business Context and Reporting Period
This Form 8-K, filed on November 6, 2024, reports on events occurring on November 5, 2024, regarding Recursion Pharmaceuticals, Inc. (RXRX). The filing details an amendment to the Transaction Agreement with Exscientia plc, under which Recursion intends to acquire Exscientia via a Scheme of Arrangement. The filing also provides supplemental disclosures to the joint proxy statement dated October 10, 2024, and updates on litigation and financial forecasts related to the proposed transaction.
Key Financial Metrics and Forecasts
The filing does not report historical GAAP financial results for Recursion or Exscientia for a specific reporting period. Instead, it presents unaudited, non-GAAP financial forecasts used in the valuation analysis for the transaction.
- Exchange Ratio: Each Exscientia share will be exchanged for 0.7729 shares of Recursion Class A Common Stock.
- Exscientia Forecasts (Risk-Adjusted):
- 2024E Net Revenue: $18 million.
- 2024E Unlevered Free Cash Flow: Negative $195 million (with Q4 2024 forecasted at negative $49 million).
- Projected profitability: EBIT turns positive in 2031 ($11 million).
- Recursion Forecasts (Risk-Adjusted):
- 2024E Net Revenue: $30 million.
- 2024E Unlevered Free Cash Flow: Negative $362 million.
- Projected profitability: EBIT turns positive in 2029 ($537 million).
- Combined Company Forecasts (Recursion-Prepared):
- 2024E Net Revenue: $18 million (Note: This table appears to reflect Exscientia-only or specific combined scenarios; context suggests distinct forecasts were prepared).
- 2024E Unlevered Free Cash Flow: Negative $174 million (Q4 2024 forecasted at negative $87 million).
- Valuation Ranges (Financial Advisor Analysis):
- Exscientia Enterprise Value (Public Companies): $124 million to $719 million.
- Exscientia Transaction Value (Precedent Transactions): $458 million to $1.011 billion.
- Exscientia Implied Equity Value (DCF): $3.90 to $6.60 per share.
Material Changes and Transaction Updates
The primary material change is the execution of the First Amendment to the Transaction Agreement on November 5, 2024. Key modifications include:
- Board Composition: Recursion will appoint one member of Exscientia's board to its own board prior to the Effective Time. Additionally, Recursion will appoint one additional individual to its board if mutually agreed upon by both parties prior to the Effective Time.
- Leadership: Dr. Chris Gibson (Recursion CEO) is expected to continue as CEO of the combined company. Dr. Andrew Hopkins (Exscientia CEO) was previously proposed to join the Recursion Board as Vice Chair.
- Transaction History: The filing clarifies that discussions began in October 2022, with a mutual confidentiality agreement signed in November 2022. A Transaction Committee was established by the Recursion Board on July 17, 2024.
Guidance, Risks, and Contingencies
Guidance and Outlook: The filing includes extensive forward-looking statements regarding the transaction's completion and the combined company's future performance. Management forecasts significant revenue growth for both entities over the next two decades, with the combined entity projecting positive EBITDA by 2031 and substantial free cash flow generation thereafter. However, Recursion explicitly states it does not publicly disclose financial forecasts as a matter of course due to uncertainty.
Risks and Contingencies:
- Shareholder Litigation: Two lawsuits were filed in New York state court in October 2024 (Elliot v. Recursion Pharmaceuticals, Inc. and Kent v. Recursion Pharmaceuticals, Inc.). Plaintiffs allege negligent misrepresentation and concealment regarding the transaction and seek to enjoin the deal. Recursion believes these claims are without merit.
- Transaction Approval: The deal is contingent upon Recursion stockholder approval, Exscientia shareholder approval, and the sanction of the High Court of Justice of England and Wales.
- Integration Risks: Risks include the inability to realize cost synergies, disruption of operations, and retention of key personnel.
- Financial Uncertainty: Both companies are currently operating at significant losses with negative free cash flow. The forecasts rely on the successful development and commercialization of drug candidates, which is inherently uncertain.
Investor Verification Checklist
- Verify the status of the pending shareholder lawsuits (Elliot and Kent) and any potential injunctions that could delay or block the transaction.
- Review the definitive joint proxy statement (filed Oct 10, 2024) for the full "Risk Factors" section and detailed terms of the Scheme of Arrangement.
- Confirm the final composition of the Recursion Board post-transaction, specifically the appointment of Exscientia directors and the additional mutually agreed-upon member.
- Assess the assumptions underlying the financial forecasts, particularly the risk-adjustment methodologies and the timeline for achieving profitability (2029-2031).
- Monitor regulatory approvals required from the UK High Court and any other relevant jurisdictions.